SCHEMBL7603092

SCHEMBL7603092

CCCCc1ccc(OC(=O)Nc2ccc(C)c(C(=O)N3CCN(c4ccccc4OC)CC3)c2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.48
TSHR P16473 2/20 0.48
MAPT P10636 4/20 0.47
GAA P10253 1/20 0.47
HPGD P15428 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
HTT P42858 2/20 0.47
RAB9A P51151 2/20 0.46
HTR1A P08908 1/20 0.45
HTR1D P28221 1/20 0.45
HTR1B P28222 1/20 0.45
HTR2A P28223 1/20 0.45
HTR2C P28335 1/20 0.45
HTR7 P34969 1/20 0.45
HTR6 P50406 1/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
LMNA P02545 1/20 0.44
NPSR1 Q6W5P4 2/20 0.44
NPC1 O15118 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7603082 0.95 ALDH1A1 (0.48) ALDH1A1TSHRMAPTGAAHPGD
SCHEMBL7607418 0.89 NPSR1 (0.49) ALDH1A1TSHRMAPTSMN1; SMN2HTT
SCHEMBL12597849 0.87 MAPT (0.53) MAPTGAAHTTRAB9AHTR2A
SCHEMBL7603987 0.85 NAMPT (0.53) ALDH1A1TSHRMAPTSMN1; SMN2HTT
SCHEMBL20976500 0.85 ALDH1A1 (0.48) ALDH1A1TSHRMAPTGAAHPGD
SCHEMBL7607167 0.85 ALDH1A1 (0.51) ALDH1A1TSHRMAPTGAAHPGD
SCHEMBL20976555 0.85 ALDH1A1 (0.47) ALDH1A1TSHRMAPTGAAHPGD
SCHEMBL21538236 0.84 ALDH1A1 (0.47) ALDH1A1TSHRMAPTGAAHPGD
SCHEMBL11996 0.84 HTT (0.60) ALDH1A1TSHRMAPTGAAHTT
SCHEMBL20976519 0.83 ALDH1A1 (0.47) ALDH1A1TSHRMAPTGAAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240071588-A1 METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS SERVIER PHARMACEUTICALS LLC (US) 2024-02-29 US disclosed
EP-3561077-B1 METHODS FOR CELL-PROLIFERATION-RELATED DISORDERS SERVIER LAB (FR) 2022-12-21 EP disclosed
US-20200281501-A1 METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS SERVIER PHARMACEUTICALS LLC 2020-09-10 US disclosed
US-10711314-B2 Methods for diagnosing IDH-mutant cell proliferation disorders AGIOS PHARMACEUTICALS, INC. (US) 2020-07-14 US disclosed
US-10610125-B2 Methods and compositions for cell-proliferation-related disorders AGIOS PHARMACEUTICALS, INC. (US) 2020-04-07 US disclosed
EP-3561077-A1 METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS Agios Pharmaceuticals, Inc. (US) 2019-10-30 EP disclosed
US-20190276894-A1 METHOD FOR TREATING CELL PROLIFERATION RELATED DISORDERS SERVIER PHARMACEUTICALS LLC 2019-09-12 US disclosed
EP-2406389-B1 METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS AGIOS PHARMACEUTICALS INC (US) 2019-05-08 EP disclosed
US-9982309-B2 Method for treating cell proliferation related disorders AGIOS PHARMACEUTICALS, INC. (US) 2018-05-29 US disclosed
US-20170325708-A1 METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS AGIOS PHARMACEUTICALS, INC. (US) 2017-11-16 US disclosed
EP-3064595-A1 METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS Agios Pharmaceuticals, Inc. (US) 2016-09-07 EP disclosed
US-9434979-B2 Methods and compositions for cell-proliferation-related disorders SERVIER PHARMACEUTICALS LLC 2016-09-06 US disclosed
EP-2491145-B1 METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS AGIOS PHARMACEUTICALS INC (US) 2016-03-09 EP disclosed
US-20150240286-A1 METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS AGIOS PHARMACEUTICALS, INC (US) 2015-08-27 US disclosed
US-20140187435-A1 METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS AGIOS PHARMACEUTICALS, INC (US) 2014-07-03 US disclosed
US-20130288284-A1 METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS SERVIER PHARMACEUTICALS LLC 2013-10-31 US disclosed
US-20130183281-A1 METHODS AND COMPOSITONS FOR CELL-PROLIFERATION-RELATED DISORDERS SERVIER PHARMACEUTICALS LLC 2013-07-18 US disclosed
US-20130035329-A1 THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE SERVIER PHARMACEUTICALS LLC 2013-02-07 US disclosed
US-20120121515-A1 METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS SERVIER PHARMACEUTICALS LLC 2012-05-17 US disclosed
WO-2010105243-A1 METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS AGIOS PHARMACEUTICALS, INC. (US) 2010-09-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10711314-B2 Methods for diagnosing IDH-mutant cell proliferation disorders MKI67, IDH1, IDH3A ALDH1A1 489/4885TSHR 4213/4885MAPT 4240/4885
US-10610125-B2 Methods and compositions for cell-proliferation-related disorders MKI67, BRCA1, CLN6 ALDH1A1 2917/4885TSHR 3817/4885MAPT 4093/4885
US-20170325708-A1 METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS MKI67, BRCA1, CLN6 ALDH1A1 2917/4885TSHR 3817/4885MAPT 4093/4885
US-20120121515-A1 METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS MKI67, BRCA1, CLN6 ALDH1A1 2917/4885TSHR 3817/4885MAPT 4093/4885
US-20240071588-A1 METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS MKI67, BRCA1, CLN6 ALDH1A1 2917/4885TSHR 3817/4885MAPT 4093/4885
US-20130183281-A1 METHODS AND COMPOSITONS FOR CELL-PROLIFERATION-RELATED DISORDERS IDH2, IDH1, MKI67 ALDH1A1 2900/4885TSHR 4272/4885MAPT 2625/4885
US-20130035329-A1 THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE MCL1, TP53, CD44 ALDH1A1 2219/4885TSHR 4602/4885MAPT 2835/4885
US-20200281501-A1 METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS MKI67, BRCA1, CLN6 ALDH1A1 2917/4885TSHR 3817/4885MAPT 4093/4885
US-20190276894-A1 METHOD FOR TREATING CELL PROLIFERATION RELATED DISORDERS IDH2, IDH1, IDH3A ALDH1A1 1072/4885TSHR 3930/4885MAPT 3070/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.